Do sodium–glucose cotransporter 2 inhibitors lead to fracture risk? A pharmacovigilance real‐world study

Pharmacologic strategies to reduce cardiovascular disease in type 2 diabetes mellitus: focus on SGLT ‐2 inhibitors and GLP ‐1 receptor agonists

(2019) A. Bonaventura et al.   JOURNAL OF INTERNAL MEDICINE

Risk of fracture with dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors in real-world use: systematic review and meta-analysis of observational studies

(2019) K. Hidayat et al.   OSTEOPOROSIS INTERNATIONAL

Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials

(2019) Giovanni Musso et al.   BMJ-British Medical Journal

A Survey of the FDA’s Adverse Event Reporting System Database Concerning Urogenital Tract Infections and Sodium Glucose Cotransporter‐2 Inhibitor Use

(2019) Juan Shen et al.   Diabetes Therapy

The use of metformin, insulin, sulphonylureas, and thiazolidinediones and the risk of fracture: Systematic review and meta-analysis of observational studies

(2019) Khemayanto Hidayat et al.   Obesity Reviews

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

(2019) Francesco Cosentino et al.   EUROPEAN HEART JOURNAL

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction

(2019) John J.V. McMurray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Long-Term Effectiveness and Safety of SGLT-2 Inhibitors in an Italian Cohort of Patients with Type 2 Diabetes Mellitus

(2019) Maria Mirabelli et al.   Journal of Diabetes Research

Pharmacovigilance assessment of the association between Fournier’s gangrene and other severe genital adverse events with SGLT-2 inhibitors

(2019) Gian Paolo Fadini et al.   BMJ Open Diabetes Research & Care

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

(2019)   DIABETES CARE

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

(2019) John B. Buse et al.   DIABETOLOGIA

Analysis of Fractures in Patients With Type 2 Diabetes Treated With Empagliflozin in Pooled Data From Placebo-Controlled Trials and a Head-to-Head Study Versus Glimepiride

(2018) Sven Kohler et al.   DIABETES CARE

SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review

(2018) Subodh Verma et al.   DIABETOLOGIA

SGLT-2 Inhibitors and Cardiovascular Risk

(2018) Matthew A. Cavender et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs

(2018) Mikhail Kosiborod et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Sodium-glucose co-transporter-2 inhibitors and the risk of fractures of the upper or lower limbs in patients with type 2 diabetes: A nested case-control study

(2018) Niklas Schmedt et al.   DIABETES OBESITY & METABOLISM

Association between glycemic control and risk of fracture in diabetic patients: A nested case-control study

(2018) Janina Vavanikunnel et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

2018 ACC Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease

(2018) Sandeep R. Das et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

(2018) Stephen D. Wiviott et al.   NEW ENGLAND JOURNAL OF MEDICINE

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

(2017) Bruce Neal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of diabetes drugs on the skeleton

(2016) Christian Meier et al.   BONE

Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

(2016) John P. Bilezikian et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus

(2016) Nelson B. Watts et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Probing SGLT2 as a therapeutic target for diabetes: Basic physiology and consequences

(2015) Linda A Gallo et al.   Diabetes & Vascular Disease Research

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

(2015) Bernard Zinman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Possible adverse effects of SGLT2 inhibitors on bone

(2015) Simeon I Taylor et al.   Lancet Diabetes & Endocrinology

Selected control events and reporting odds ratio in signal detection methodology

(2010) Nobuhiro Ooba et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY